ARCHIVED Guidance on applications for drug clinical trials under the interim order: Post-authorization requirements

Notice to Reader:

We have replaced the Interim Order No. 2 respecting clinical trials for medical devices and drugs relating to COVID-19. See the regulations notice about the Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations.

On this page

Suspending a clinical trial

Under section 29 of IO No. 2, Health Canada may suspend authorization of a COVID-19 drug clinical trial, in whole or in part, if:

For example, Health Canada will be able to suspend 1 arm, or treatment group, of a multi-arm trial, if needed. This makes it possible for the rest of the trial to proceed so that other patients can continue to receive a promising therapy.

Note: All suspensions, in whole or part, for clinical trials issued under IO No. 1 will remain in effect under IO No. 2.

Reinstating a clinical trial

Health Canada must reinstate a suspended trial if the holder of the suspended authorization:

Additional information

Health Canada may request additional information, materials or samples when deciding whether to issue, amend or suspend a clinical trial authorization. This information must be provided within the time, form and manner specified by Health Canada.

Note: A request that was made by Health Canada under IO No. 1 continues to be in effect under IO No. 2.

Discontinuing a clinical trial

As per section 31 of IO No. 2, if an authorization holder discontinues a previously authorized COVID-19 drug clinical trial, in whole or in part, the holder must notify Health Canada as soon as possible in writing. (See Who to contact.)

All qualified investigators must also be informed in writing.

As well, the holder must stop the importation or sale of the drug at each clinical trial site at which the trial has been discontinued.

For information on the requirements and what should be included in the notification, please refer to section 2.8.1 of the Guidance document for clinical trial sponsors: Clinical trial applications.

If the authorization holder discontinues and subsequently wants to resume their trial, they will have to refile a new clinical trial application.

Note: A notice of discontinuance that was provided to Health Canada in IO No. 1 continues to be in effect under IO No. 2.

Revoking a clinical trial

Mandatory revocation

When we receive a notice of discontinuance of the COVID-19 drug clinical trial by an authorization holder, Health Canada must revoke, in whole or in part, the authorization.

Discretionary revocation

Health Canada may, at any time, revoke, in whole or in part, the authorization if the holder fails to provide satisfactory information following a suspension. This includes:

Notice/transparency

Following a mandatory or discretionary revocation, Health Canada will issue a cancellation letter to the authorization holder. We will either confirm we have received the notice of discontinuation (mandatory revocation) or give reasons for the revocation (discretionary revocation).

We will update information on the status of the COVID-19 drug clinical trial following a revocation on our vaccines and treatments for COVID-19 webpage and clinical trial database.

Note: A COVID-19 drug authorization that was revoked in part by Health Canada under IO No. 1, and has not been revoked in whole since, will continue to be considered revoked in part under IO No. 2.

Serious unexpected adverse drug reactions

Subsection C.05.014(1) of Division 5 of the Regulations, which covers serious unexpected adverse drug reactions, was carried over into section 34 of IO No. 2. In line with existing guidance, the authorization holder must inform us of all serious unexpected adverse drug reactions from a drug used during a COVID-19 drug clinical trial:

Records

Existing requirements under C.05.012 of Division 5 of the Regulations on the maintenance of complete and accurate records have been carried over into Section 35 of IO No. 2.

For information on the records that must be maintained, please refer to section 2.8.6 of the Guidance document for clinical trial sponsors: Clinical trial applications.

The authorization holder must maintain all records for the period that IO No. 2 is in force (that is, 1 year). However, these should be kept beyond this time frame in line with existing clinical trial guidance and Division 5 requirements.

Page details

Date modified: